-
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
•
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with Neomorph, Inc., aimed at developing novel molecular glue degraders for multiple targets across oncology and immunology. The partnership seeks to leverage Neomorph’s innovative technology to address critical needs in cancer and immune-related diseases. Molecular Glue…
-
Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases
•
U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop molecular glue degraders targeting key areas in Alzheimer’s, rare neurological disorders, and immunological diseases. Leveraging Neomorph’s proprietary molecular glue discovery platform, the partnership aims to enhance the identification and validation of novel small-molecule therapeutic degraders…
